Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Jacob M. Sands; Sumithra J. Mandrekar; David Kozono; Geoffrey R. Oxnard; Shauna L. Hillman; Dennis A. Wigle; Ramaswamy Govindan; Jennifer Carlisle; Jhanelle Gray; Joseph K. Salama; Luis Raez; Apar Ganti; Nathan Foster; Shakun Malik; Jeffrey Bradley; Karen Kelly; Suresh S. Ramalingam; Thomas E. Stinchcombe

doi:10.2217/imt-2021-0019

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Jacob M. Sands, Sumithra J. Mandrekar, David Kozono, Geoffrey R. Oxnard, Shauna L. Hillman, Dennis A. Wigle, Ramaswamy Govindan, Jennifer Carlisle, Jhanelle Gray, Joseph K. Salama, Luis Raez, Apar Ganti, Nathan Foster, Shakun Malik, Jeffrey Bradley, Karen Kelly, Suresh S. Ramalingam, Thomas E. Stinchcombe

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.

Original language	English
Pages (from-to)	727-734
Number of pages	8
Journal	Immunotherapy
Volume	13
Issue number	9
DOIs	https://doi.org/10.2217/imt-2021-0019
State	Published - Jun 2021

Keywords

NSCLC
adjuvant chemotherapy
lung adenocarcinoma
lung squamous cell carcinoma
pembrolizumab

Access to Document

10.2217/imt-2021-0019

Cite this

Sands, J. M., Mandrekar, S. J., Kozono, D., Oxnard, G. R., Hillman, S. L., Wigle, D. A., Govindan, R., Carlisle, J., Gray, J., Salama, J. K., Raez, L., Ganti, A., Foster, N., Malik, S., Bradley, J., Kelly, K., Ramalingam, S. S., & Stinchcombe, T. E. (2021). Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). Immunotherapy, 13(9), 727-734. https://doi.org/10.2217/imt-2021-0019

@article{4aa0bc342e284fb98e5da102beb465ba,

title = "Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)",

abstract = "Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.",

keywords = "NSCLC, adjuvant chemotherapy, lung adenocarcinoma, lung squamous cell carcinoma, pembrolizumab",

author = "Sands, {Jacob M.} and Mandrekar, {Sumithra J.} and David Kozono and Oxnard, {Geoffrey R.} and Hillman, {Shauna L.} and Wigle, {Dennis A.} and Ramaswamy Govindan and Jennifer Carlisle and Jhanelle Gray and Salama, {Joseph K.} and Luis Raez and Apar Ganti and Nathan Foster and Shakun Malik and Jeffrey Bradley and Karen Kelly and Ramalingam, {Suresh S.} and Stinchcombe, {Thomas E.}",

year = "2021",

month = jun,

doi = "10.2217/imt-2021-0019",

language = "English",

volume = "13",

pages = "727--734",

journal = "Immunotherapy",

issn = "1750-743X",

number = "9",

}

Sands, JM, Mandrekar, SJ, Kozono, D, Oxnard, GR, Hillman, SL, Wigle, DA, Govindan, R, Carlisle, J, Gray, J, Salama, JK, Raez, L, Ganti, A, Foster, N, Malik, S, Bradley, J, Kelly, K, Ramalingam, SS & Stinchcombe, TE 2021, 'Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)', Immunotherapy, vol. 13, no. 9, pp. 727-734. https://doi.org/10.2217/imt-2021-0019

TY - JOUR

T1 - Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer

T2 - ALCHEMIST chemo-IO (ACCIO)

AU - Sands, Jacob M.

AU - Mandrekar, Sumithra J.

AU - Kozono, David

AU - Oxnard, Geoffrey R.

AU - Hillman, Shauna L.

AU - Wigle, Dennis A.

AU - Govindan, Ramaswamy

AU - Carlisle, Jennifer

AU - Gray, Jhanelle

AU - Salama, Joseph K.

AU - Raez, Luis

AU - Ganti, Apar

AU - Foster, Nathan

AU - Malik, Shakun

AU - Bradley, Jeffrey

AU - Kelly, Karen

AU - Ramalingam, Suresh S.

AU - Stinchcombe, Thomas E.

PY - 2021/6

Y1 - 2021/6

N2 - Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.

AB - Non-small-cell lung cancer (NSCLC) causes significant mortality each year. After successful resection of disease stage IB (>4 cm) to IIIA (per AJCC 7), adjuvant platinum-based chemotherapy improves median overall survival and is the standard of care, but many patients still experience recurrence of disease. An adjuvant regimen with greater efficacy could substantially improve outcomes. Pembrolizumab, a programmed cell death-1 inhibitor, has become an important option in the treatment of metastatic NSCLC. ALCHEMIST is a clinical trial platform of the National Cancer Institute that includes biomarker analysis for resected NSCLC and supports therapeutic trials including A081801 (ACCIO), a three-arm study that will evaluate both concurrent chemotherapy plus pembrolizumab and sequential chemotherapy followed by pembrolizumab to standard of care adjuvant platinum-based chemotherapy. Clinical trial registration: NCT04267848 (ClinicalTrials.gov.

KW - NSCLC

KW - adjuvant chemotherapy

KW - lung adenocarcinoma

KW - lung squamous cell carcinoma

KW - pembrolizumab

UR - http://www.scopus.com/inward/record.url?scp=85105906321&partnerID=8YFLogxK

U2 - 10.2217/imt-2021-0019

DO - 10.2217/imt-2021-0019

M3 - Article

C2 - 33878954

AN - SCOPUS:85105906321

SN - 1750-743X

VL - 13

SP - 727

EP - 734

JO - Immunotherapy

JF - Immunotherapy

IS - 9

ER -

Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO)

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this